جست‌وجوی استاد و پژوهشگر

• Healthcare Robotics
• Neuroethics
• Public Health
• +۵ مورد دیگر

Kirsten Brukamp ist Professorin für Gesundheitswissenschaften (Medizinische Kontexte der Pflege) an der Evangelischen Hochschule Ludwigsburg. Ihr Forschungsschwerpunkt umfasst die interdisziplinäre Verantwortung für Innovationen in Gesundheitstechnologien, Neuromedizin, Neuroethik und die evidenzbasierte Gestaltung des Gesundheitswesens. Sie ist in mehreren Forschungsprojekten zu assistiven Technologien und ethischen Implikationen moderner Medizin tätig. Ihre akademische Ausbildung umfasst eine Promotion in Humanmedizin an der Universität Münster, einen M.Sc. in Kognitionspsychologie an der Universität Osnabrück und einen M.A. in Philosophie an der Universität Münster. Berufliche Stationen umfassen Forschungsaufenthalte an renommierten Institutionen wie Albert Einstein College of Medicine, University of Pennsylvania und Harvard University. Professorin für Gesundheitswissenschaften: Medizinische Kontexte der Pflege Leitung der ersten Programmakkreditierung eines Masterstudiengangs für Gesundheits-, Pflege- und Therapiewissenschaften Dozentin für Geschichte, Theorie und Ethik der Medizin Ihre Forschungsinteressen konzentrieren sich auf die Entwicklung von Gesundheitstechnologien mit besonderem Fokus auf Neurotechnologien für Menschen mit schweren Hirnschädigungen, Virtual Reality in der medizinischen Anwendung und medizinethische Fragestellungen im Zusammenhang mit chronischen Erkrankungen. Die Veröffentlichungen der letzten Jahre zeigen einen klaren Schwerpunkt auf assistive Robotics , telemedizinische Lösungen und ethische Implikationen neuer Technologien in der Pflege. Kontakt: k.brukamp@eh-ludwigsburg.de

• Stem Cell Therapy
• Gene Therapy
• Regenerative Medicine
• +۵ مورد دیگر

Pascale V Guillot is a Professor of Stem Cell and Gene Therapy at University College London, based at the Zayed Centre for Research into Rare Diseases in Children (ZCR) within the Great Ormond Street Institute of Child Health. She specializes in Maternal & Fetal Medicine with a research focus on developing stem cell-based therapies for rare pediatric conditions, particularly osteogenesis imperfecta and neonatal brain injuries. Her work bridges laboratory research with potential clinical applications through innovative approaches using amniotic fluid stem cells and gene editing technologies. Her research interests center on regenerative medicine approaches for rare childhood diseases. Guillot leads the Laboratory of Stem Cell and Exosome Therapy, which combines induced pluripotent stem cells and gene editing to design nanotherapeutics targeting skeletal disorders like osteogenesis imperfecta (brittle bone disease) and neurological conditions including neonatal encephalopathy and stroke. Her work demonstrates particular expertise in amniotic fluid stem cells, their differentiation potential, and therapeutic applications in both bone and brain disorders. Analysis of her publication record reveals a consistent trajectory focused on translational stem cell research. Her most recent work (2024-2025) shows expansion into clinical applications of previously developed therapies, including real-world efficacy studies. Throughout her career, Guillot has maintained strong focus on amniotic fluid and fetal stem cells, with progressive refinement from basic characterization to therapeutic applications, particularly in skeletal and neurological disorders. Her research demonstrates significant interdisciplinary integration of cell biology, nanomedicine, and clinical pediatrics. Guillot maintains active collaborations across multiple institutions as evidenced by her extensive co-authorship network. Her laboratory at the Zayed Centre utilizes advanced techniques including micro-computed tomography for bone analysis and sophisticated stem cell characterization methods. She has contributed significantly to understanding the therapeutic potential of various stem cell populations, particularly those derived from amniotic fluid and fetal tissues, with emphasis on their application in rare genetic disorders affecting children.

• Glycocalyx
• Diabetes
• Albuminuria
• +۷ مورد دیگر

Dr. Matthew J Butler serves as a Consultant Senior Lecturer and MRC Clinician Scientist at Bristol Medical School, University of Bristol. His clinical-academic role bridges medical practice with cutting-edge research in vascular biology and diabetic complications. Holding qualifications including BSc, MBChB, and PhD, he maintains active clinical duties alongside research leadership. His research focuses on endothelial glycocalyx dysfunction in diabetes and kidney disease, with specialization in aldosterone-mediated vascular damage, albuminuria mechanisms, and glomerular filtration barrier pathology. Key areas include glycocalyx repair strategies , mineralocorticoid receptor signaling , and microvascular complication prevention . His work integrates molecular biology, animal models, and clinical translation. Recent publications analyze adiponectin's protective effects on glomerular function (2024), heparanase inhibition for glycocalyx preservation (2024), and aldosterone's dual roles in vascular health (2023). His research demonstrates consistent focus on endothelial barrier integrity across diabetic nephropathy, hypertension, and metabolic syndrome. As Co-Investigator on the MRC-funded project Determining The Therapeutic Potential Of Gene Therapy For Translation Of Glycocalyx Protection Strategies In Chronic Kidney Disease (2024-2025), he leads translational efforts toward clinical applications. His PhD thesis ( Aldosterone-induced endothelial glycocalyx dysfunction, a potential therapeutic target in proteinuria? , 2018) established foundational work in this field. His laboratory collaborates extensively with renal and vascular research groups, utilizing advanced techniques including intravital microscopy and genetic models. Current work emphasizes therapeutic glycocalyx restoration strategies for diabetic microvascular complications.

• Nephrology
• Diabetic Kidney Disease
• Glomerular Diseases
• +۵ مورد دیگر

Jenny Nyström is a Professor at the University of Gothenburg , affiliated with the Sahlgrenska Academy and the Department of Neuroscience and Physiology . Her research focuses on kidney function and glomerular kidney diseases , particularly mechanisms of lipotoxicity, proteomic changes, and molecular pathways in diabetic kidney disease. Key areas: Podocyte biology, VEGF signaling, proteomics, and microRNA regulation Collaborations: Extensive co-authorships with researchers in nephrology, diabetes, and molecular medicine Recent publications highlight trends in proteomic analysis of kidney injuries , lipid metabolism in renal diseases , and microRNA interactions in glomerular dysfunction . Her work bridges basic science and clinical applications, emphasizing diabetic nephropathy and inflammatory kidney pathologies.

Uwe Völkerمشاهده پروفایل

استاد

• Microbial Physiology
• Transcriptome Analysis
• Proteome Analysis
• +۲ مورد دیگر

Prof. Dr. Uwe Völker serves as the Head of the Department of Functional Genomics at the Interfaculty Institute of Genetics and Functional Genome Research, University of Greifswald. His academic leadership spans microbial physiology and advanced omics methodologies, with institutional affiliation rooted in Germany's historic Greifswald academic community. His research program centers on: Microbial physiology under diverse environmental conditions Comprehensive transcriptome and proteome analyses of pathogenic microorganisms In-vivo proteomics to dissect host-pathogen interaction dynamics Mechanistic studies of bacterial virulence regulation systems Recent publications (2024-2025) reveal a dominant focus on Staphylococcus aureus and Streptococcus pneumoniae pathogenesis, with recurring themes in RNA-mediated regulation, stress response mechanisms, and post-translational modifications. His work bridges microbial genomics with clinical applications in thrombosis, nephrology, and inflammation, demonstrating consistent multi-omics integration across 15+ annual publications. Key methodological strengths include mass spectrometry-based proteomics, transcriptomic profiling, and molecular genetics approaches applied to host-pathogen systems. As departmental head, Völker directs a research ecosystem investigating bacterial adaptation mechanisms through functional genomics, with particular emphasis on virulence factor regulation under nutrient stress and host immune pressure. His team's work on sRNA networks (e.g., IsrR in S. aureus) and proteome remodeling provides critical insights into infectious disease progression.

• Metabolic Disorders
• Inborn Errors of Metabolism
• Phenylketonuria
• +۵ مورد دیگر

Sören Waldemar Gersting is a University Professor (Univ. Prof. Dr.) at the University Medical Center Hamburg-Eppendorf, where he serves in the Department of Pediatrics and Adolescent Medicine within the Faculty of Medicine. His extensive research portfolio demonstrates significant contributions to metabolic disorders, pediatric immunology, and personalized medicine approaches for inborn errors of metabolism. Dr. Gersting's research focuses primarily on metabolic disorders, particularly phenylketonuria and glutaric acidemia. His work spans from fundamental biochemical investigations of enzyme function and protein misfolding to clinical applications of personalized treatment approaches. He has made notable contributions to understanding genotype-phenotype correlations in metabolic diseases and developing novel therapeutic strategies including pharmacological chaperones. His research integrates biochemistry, molecular biology, genetics, and clinical medicine, with recent work demonstrating increasing interdisciplinary collaboration across computational biology, structural biology, and clinical research. His publication record shows consistent productivity with research spanning from 2021 through 2025, with recent work demonstrating an expanding scope that includes computational approaches to drug discovery, pediatric immunology (particularly related to SARS-CoV-2 responses in children), and the molecular mechanisms underlying rare metabolic disorders. His work on the Site-Directed Enzyme Enhancement Therapy (SEE-Tx) platform represents a significant advancement in developing targeted treatments for metabolic disorders. Dr. Gersting has been actively involved in medical education, as evidenced by his work on designing structured postgraduate training programs using agile methods. His research group appears to collaborate extensively with colleagues across multiple institutions, particularly in the areas of pediatric hepatology, immunology, and metabolic disorders, indicating a highly interdisciplinary research program with significant clinical implications.

Malte Gatherمشاهده پروفایل

استاد

• Biophotonics
• Biophysics
• Organic Electronics
• +۶ مورد دیگر

Professor Malte Gather is a distinguished academic at the University of St Andrews, holding a position in the School of Physics and Astronomy. He maintains multiple significant affiliations including the Sir James Mackenzie Institute for Early Diagnosis, Centre for Biophotonics, Biomedical Sciences Research Complex, Institute of Behavioural and Neural Sciences, and Organic Semiconductor Centre. His research spans the intersection of physics, biology, and engineering, focusing on innovative optical technologies with biomedical applications. Professor Gather's research interests encompass three primary domains: Biophotonics & biophysics (bio-derived optical structures, biological lasers, cellular biomechanics, and nanophotonic biosensors); Organic electronics / OLEDs (nano/micro-patterning of organic semiconductors, OLED optics, and organic electronics for lab-on-chip systems); and Plasmonics (plasmonic lasers, molecular plasmonics, and plasmonic sensors). His work demonstrates a consistent focus on developing novel optical tools for biological investigation and medical applications. Analysis of Professor Gather's recent publications reveals a strong trend toward biomedical applications of photonic technologies, particularly in cellular mechanics, kidney disease research, and neural interfaces. His work bridges fundamental physics with practical medical solutions, often involving interdisciplinary collaborations between physicists, biologists, and medical researchers. The research increasingly focuses on translational applications with potential clinical impact. 2016 Paterson Medal and prize of the Institute of Physics Professor Gather actively supervises graduate students and postdoctoral researchers, with recent thesis projects focusing on high-efficiency OLEDs for optogenetics and biophotonic tools for cellular mechanics imaging. His research is supported by significant grants including the TRACER project (EPSRC), IBIS project, and multiple BBSRC-funded initiatives. He leads the Gather Lab, which maintains a strong focus on developing innovative optical technologies with biomedical applications, particularly in the areas of biological lasers, cellular biomechanics, and organic optoelectronics for medical devices.

• Nephrology
• Glomerular Diseases
• Podocyte Biology
• +۵ مورد دیگر

Andrey V. Cybulsky is a Senior Scientist at the Research Institute of the McGill University Health Centre (RI-MUHC) and a Professor in the Department of Medicine at McGill University . His research focuses on understanding the molecular mechanisms of glomerular diseases, particularly those involving podocyte injury and immune-mediated processes. Key research areas include: Pathophysiology of glomerulonephritis Role of phospholipases and protein kinases in renal injury Endoplasmic reticulum stress and proteostasis in podocytes Therapeutic targeting of SLK (Ste20-like kinase) and IRE1α pathways Recent work highlights: Genetic models of phospholipase A2γ deletion in diabetic nephropathy Mechanistic studies on IRE1α-mediated ER-phagy Development of urinary biomarkers for ER stress SLK regulation of cytoskeletal dynamics in podocytes His publications span high-impact nephrology and molecular biology journals, with a focus on translational approaches to chronic kidney disease.

• cGMP signaling
• Signal transduction
• Transgenic mouse models
• +۳ مورد دیگر

Professor Robert Feil leads the Department of Signal Transduction & Transgenic Models at the Interfaculty Institute for Biochemistry , University of Tübingen. His research focuses on cGMP signaling pathways across cardiovascular, neurological, and cancer contexts, utilizing "in vivo biochemistry" and advanced optical imaging technologies in transgenic mouse models. Current affiliations: Spokesperson for DFG Research Training Group GRK 2381 (2019-present) and member of GRK 2816 Research highlights: Mechanosensitive cGMP signaling, tumor-vascular interactions, CNP/GC-B signaling in kidney development, and novel insights into atherosclerosis mechanisms Recent work emphasizes cell fate mapping through CreER technology and real-time cGMP visualization in living systems. His lab has produced significant findings on vascular smooth muscle cell plasticity and macrophage-like cell transdifferentiation in atherosclerotic plaques. Key trainees include: PhD candidates: Kevin Dervishi (mechanosensitive signaling), Alisa Groh (tumor vessel signaling), Shahzad Munir (hippocampal signaling), Daniel Pinto Quintero (platelet signaling), and Asli Pektas (developmental physiology) Past doctoral researchers: Timo Kopp (2024 graduate), Daniel Stehle (2023 graduate) Technological innovations: Developed CreER T2 for inducible gene targeting Created cGMP biosensors for in vivo imaging

Rudiyanto Gunawanمشاهده پروفایل

دانشیار

• Systems Biology
• Bioinformatics
• Computational Biology
• +۹ مورد دیگر

Rudiyanto Gunawan is an Associate Professor in the Department of Chemical and Biological Engineering at the University at Buffalo, leading the Chemical and Biological Systems Engineering Laboratory (CABSEL). His research focuses on computational systems biology, bioinformatics, and mathematical modeling to understand biological networks and their applications in biopharmaceutical manufacturing, drug discovery, and aging. He holds academic appointments at institutions including ETH Zurich and the National University of Singapore, and is active in professional organizations such as the American Institute of Chemical Engineers (AIChE). Education includes a Ph.D. in Chemical Engineering from the University of Illinois Urbana-Champaign (2003), with prior roles as a postdoctoral fellow at UC Santa Barbara and research assistant at UIUC. His professional activities span editorial roles, conference organizing, and committee service in systems biology and computational biology. Research interests include network inference, dynamical systems modeling, and design of experiments, applied to areas like mitochondrial DNA mutagenesis, stem cell differentiation, and glycosylation pathways. He has contributed to tools like DeltaNeTS+, CrossTx, and GlycoEnzOnto, aiming to bridge large-scale biological data with actionable insights for disease intervention. His work integrates single-cell transcriptomics, metabolic flux analysis, and machine learning to address challenges in aging, neurobiology, and biopharmaceutical processes. CABSEL’s projects emphasize translational applications, such as optimizing monoclonal antibody production and understanding Alzheimer’s disease mechanisms through systems approaches.

• Kidney Transplantation
• Nephrology
• Immunosuppression
• +۵ مورد دیگر

Dr. Flavio Vincenti is a Professor of Medicine at the University of California, San Francisco (UCSF) School of Medicine, where he has been on faculty since 1975. He serves in the Department of Medicine's Division of Nephrology and has been actively involved with the transplant service since 1976, focusing on patient care and clinical trials with novel immunosuppression drugs. Dr. Vincenti completed his medical residency at the University of California, San Francisco School of Medicine, establishing the foundation for his long career in nephrology and transplantation medicine. Dr. Vincenti's research focuses on advancing kidney transplantation through innovative immunosuppression strategies, particularly costimulation blockade with agents like belatacept. His work spans from basic immunological investigations to large-scale clinical trials that have transformed transplantation practices. He has pioneered research in desensitization protocols for highly sensitized patients, novel biological agents for immunosuppression, and precision medicine approaches to transplantation. His expertise in clinical trial design has made him a leader in evaluating new therapies for transplant recipients, with particular attention to improving long-term outcomes while minimizing complications. Analysis of Dr. Vincenti's recent publications (2023-2025) reveals a continued emphasis on precision medicine approaches in transplantation, with particular focus on desensitization therapies for highly sensitized kidney transplant candidates, management of complications like neutropenia in transplant recipients, and novel biological agents for immunosuppression. His work bridges basic immunology with clinical applications, often focusing on B-cell and plasma cell biology in the context of transplant rejection, and includes important contributions to race-neutral kidney function assessment and management of post-transplant infections. Dr. Vincenti has received significant research funding throughout his distinguished career, most notably as Principal Investigator on the AMELIORATE study (NIH U01AI113362, 2014-2024) which applies precision medicine to optimize desensitization with novel biologics or cellular therapies in highly sensitized kidney transplant patients. He was also a Co-Investigator on the General Clinical Research Center grant (NIH M01RR000079, 1974-2009), demonstrating his long-standing commitment to advancing clinical research in transplantation. Dr. Vincenti has mentored numerous researchers and clinicians in the field of transplantation, contributing significantly to the next generation of transplant specialists. His research has been supported by multiple NIH grants and industry collaborations, reflecting his leadership in clinical trial design and execution in the transplantation field. He has played a pivotal role in numerous landmark studies that have shaped current immunosuppression protocols and clinical practices in kidney transplantation worldwide. Dr. Vincenti leads research teams focused on translational studies in kidney transplantation, with particular emphasis on immune monitoring, biomarker development, and novel therapeutic approaches for difficult-to-treat transplant patients, especially those who are highly sensitized. His laboratory and clinical research programs work collaboratively to bridge discoveries from bench to bedside, with the ultimate goal of improving long-term outcomes for transplant recipients.

Hermann Hallerمشاهده پروفایل

استاد

• Proteinuria
• Renal Physiology
• Kidney Disease Mechanisms
• +۳ مورد دیگر

Hermann Haller is a Professor at the Graduate School of Biomedical Science and Engineering, University of Maine, and serves as President of the MDI Biological Laboratory. His research focuses on understanding the pathophysiology of proteinuria in kidney disease, leveraging zebrafish models to identify novel therapeutic targets. He holds an M.D. from the Free University of Berlin and completed training at Yale University School of Medicine. His research group investigates endothelial cell differentiation, glycocalyx function, and cytokine communication between endothelial cells and podocytes. They developed a zebrafish proteinuria screening system using transgenic fish and fluorescent plasma proteins. This model is used to study genetic and environmental factors influencing kidney capillary permeability, including the role of PKC isoforms in diabetes and inflammation. Collaborations include the Jackson Laboratory and Maine Medical Center for translational research through the reMAINE Healthy initiative, aiming to bridge laboratory discoveries with clinical tools for early detection of chronic kidney disease. This program integrates zebrafish and mouse models with patient data to advance diagnostics and therapies. Laboratory techniques include confocal microscopy, electron microscopy, and genetic knockdown strategies. His work emphasizes high-throughput screening for therapeutic targets, combining molecular biology with clinical partnerships to address a major public health issue.

Janos Peti Peterdiمشاهده پروفایل

استاد

• Renal Physiology
• Kidney Pathophysiology
• Cardiovascular Regulation
• +۷ مورد دیگر

Dr. Janos Peti-Peterdi is a Professor of Physiology & Biophysics and Medicine at the University of Southern California's Keck School of Medicine, where he has been tenured since 2007. As Director of the NIH-funded Multi-Photon Microscopy Core, he pioneered intravital multiphoton microscopy techniques to study kidney (patho)physiology, focusing on mechanisms of body fluid/electrolyte regulation, blood pressure control, and chronic kidney disease. Department of Physiology and Biophysics Department of Medicine Director, ZNI Multiphoton Core Facility Acting Vice Chair of Physiology & Neuroscience His research explores: Kidney injury and regeneration mechanisms using serial multiphoton imaging Macula densa cell signaling in hypertension and diabetes Endothelial glycocalyx regulation of glomerular filtration Renin secretion dynamics and therapeutic targeting Renal stem cell fate in tissue repair Development of regenerative therapies for kidney diseases Recent publications reveal trends in: Podocyte glycocalyx alterations in diabetes Neuronally differentiated endothelial cells in vascular regulation Novel imaging techniques for intrarenal ion dynamics mTORC1 signaling in aging-related kidney function Therapeutic targeting of macula densa cells Kidney-brain crosstalk via CCN1 Scientific honors include: Carl W. Gottschalk Research Scholar Award (ASN) Young Investigator Award (APS Renal Section) American Heart Association Established Investigator Dr. Peti-Peterdi serves as Associate Editor for American Journal of Physiology Renal Physiology and directs a core facility training over 30 international researchers in kidney imaging techniques.

Yousang Gwackمشاهده پروفایل

استاد

• Calcium Signaling
• Immunology
• T Cell Biology
• +۷ مورد دیگر

Dr. Yousang Gwack serves as Professor and Department Vice Chair in the Department of Physiology at the David Geffen School of Medicine, University of California Los Angeles. With over two decades of research experience, his work has significantly advanced our understanding of calcium signaling in immune cells, particularly focusing on CRAC channels and their role in T cell function. Dr. Gwack's research primarily centers on calcium signaling mechanisms in T lymphocytes, with special emphasis on CRAC channels (Orai1, STIM1, and CRACR2A). His laboratory investigates how calcium signaling regulates T cell differentiation, particularly Th17 cells, and its implications for autoimmune diseases, cancer immunology, and inflammatory disorders. His work bridges basic molecular mechanisms with clinical applications, exploring connections between immune function and conditions ranging from oral inflammation to cardiovascular disease. Analysis of Dr. Gwack's recent publications (2021-2025) reveals several key trends: a continued focus on CRAC channel biology in immune cells, expanding research into the metabolic regulation of T cells, growing interest in the role of calcium signaling in cancer stemness and tumor immunity, and emerging work connecting calcium signaling pathways to viral immunity including SARS-CoV-2 response. His research demonstrates a clear trajectory from basic channel characterization toward translational applications in inflammatory diseases and cancer. NIH R21AI149236 (2020-2022): Principal Investigator for research on ORAI3 channels in effector T cell response NIH R01AI146615 (2020-2025): Principal Investigator for research on calcium signaling in local effector T cells NIH R56AI146615 (2019-2020): Principal Investigator for research on Orai1 trafficking NIH R03AI147063 (2019-2021): Principal Investigator for research on severe neutrophilic asthma models NIH R21DE028269 (2018-2021): Co-Principal Investigator for research on histone demethylase in oral inflammation Dr. Gwack maintains an active research program with numerous collaborations across UCLA and with international partners. His laboratory has trained numerous postdoctoral fellows and graduate students who have gone on to establish independent research careers. Current work focuses on the intersection of calcium signaling, T cell metabolism, and immune-mediated diseases, with potential therapeutic applications for autoimmune conditions and cancer immunotherapy.

Fawaz Hajمشاهده پروفایل

استاد

• Metabolic Diseases
• Type 2 Diabetes
• Protein Tyrosine Phosphatases
• +۴ مورد دیگر

Dr. Fawaz Haj is a Professor in the Department of Nutrition and Internal Medicine at the University of California, Davis. His research focuses on the molecular basis of metabolic diseases, particularly type 2 diabetes and its complications, using cellular imaging, mouse models, and gene knockout techniques. Education B.Sc., Biology, American University of Beirut M.Sc., Biomedical Sciences, Bradford University D.Phil., Physiology, Oxford University Research interests include protein tyrosine phosphatases, metabolic regulation, and the role of signaling molecules in diabetes and obesity. Recent work spans IL-6 trans signaling in liver disease, nanoplastics' metabolic effects, and Shp2's role in renal function under hyperglycemia. Scientific Awards Oxford Overseas Bursaries (1997) American Diabetes Association Junior Faculty Award (2006) Hellman Fellow (2008) Faculty Leadership Academy (2018) LEAD21 National Faculty Leadership Program (2019) Dr. Haj has advised students like Grace LeBleu, who received multiple awards in 2024. He has held administrative roles such as Director of the Meyer Hall Animal Facility and Vice-Chair of the Nutrition Department (2018–2024). Labs and teams include the Meyer Hall Animal Facility and the Metabolism and Endocrinology Core at UC Davis. He actively collaborates internationally, such as moderating a U.S.–Kuwait precision medicine workshop in February 2025.